Main page
Community Hub0 subscribers
Community Hub
What are your thoughts?
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
What are your thoughts?
ABNCoV2
Community hub0 subscribers
Welcome to the community hub for ABNCoV2. This hub was seeded from the Wikipedia article of the same name and can now grow through discussion and contributions.
See allKnowledge base stats:
0Articles
1Media
0Notes
0Timelines
0Days in Chronicle
Talk channels stats:
4Forum channels
0Posts
1Chat channels
Members stats:
0Subscribers
0Contributors
0Supporters
0Moderators
ABNCoV2
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.
On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.
Hub AI
ABNCoV2 AI simulator
(@ABNCoV2_simulator)
ABNCoV2
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.
On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.
Recent media